Clinical trials: Genital Diseases, Female
Bacterial Vaginosis, Vulvovaginal Candidiases
Light Treatment of Vaginal Infections in Reproductive Age Women
Antimicrobials have helped in managing vaginal dysbiotic conditions such as bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC).
- Trial name
- NCT06985433
- Testing
- Vaginal light therapy - Once, Vaginal Light Therapy - Twice
- Where
- Denmark
- Volunteers
- 38 people
- Sponsor
- UVISA Health ApS
Advanced Solid Tumors, Ovarian Cancer
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability and determine the MTD to subsequently define an RP2D of alisertib in combination with weekly paclitaxel in East Asian participants with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
- Trial name
- NCT02367352
- Testing
- Alisertib, Paclitaxel
- Where
- 3 sites in Japan, South Korea
- Volunteers
- 9 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial…
- Trial name
- EB-DUALNK-OV (NCT07589543)
- Testing
- EB-DUALNK, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Cancer., Melanoma.
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
This study is a clinical trial phase I/II. Its goal is to determine the safety, tolerability, immunogenicity and efficacy of a therapeutic vaccine with the tumor antigen NY-ESO-1 combined with the adjuvant MPLA from B.
- Conditions
- Cancer., Melanoma., Ovarian Cancer., Lung Cancer.
- Trial name
- NCT01584115
- Testing
- NY-ESO-1 combined with MPLA, NY-ESO-1 combined with MPLA vaccine
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Instituto de Investigação em Imunologia
Ovarian Cancer
Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer
This study is designed to assess the therapeutic efficacy and toxicity of the combination chemotherapy Paclitaxel and Carboplatin with Pembrolizumab in patients with advanced ovarian cancer.
- Trial name
- MITO28MaNGOov4 (NCT03410784)
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 13 sites in Italy
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute, Naples
Endometriosis, Endometriosis Related Pain
Efficacy of Physical Therapy Treatment in Endometriosis and Its Relationship to Adherence Rates.
The main objective of this study is to know if the application of both therapies, neuroscience pain education plus therapeutic exercise will modify pain, catastrophizing and quality of life in endometriosis.
- Conditions
- Endometriosis, Endometriosis Related Pain, Endometriosis, Pain, Endometriosis-related Pain
- Trial name
- NCT06795243
- Testing
- PAIN NEUROSCIENCE EDUCATION AND THERAPEUTIC EXERCISE PROGRAM, USUAL CARE
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- University of Seville
Kidney Cancer, Melanoma (Skin)
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients with newly diagnosed brain metastases from kidney cancer…
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00003308
- Testing
- stereotactic radiosurgery
- Where
- 14 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Bleeding, Implants
Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
The etonogestrel (ENG) subdermal contraceptive implant (ENG implant) is a highly effective method of preventing pregnancy, but it has bleeding side effects that make it unappealing for many women.
- Conditions
- Bleeding, Implants, Breakthrough Bleeding
- Trial name
- Tamoxifen/BTB (NCT02903121)
- Testing
- Tamoxifen, Tamoxifen (open label)
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Ovarian Cancer
Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.
- Trial name
- NCT00345540
- Testing
- NOV-002, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Cellectar Biosciences, Inc.
Menorrhagia, Heavy Menstrual Bleeding
Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss
The objective of this study is to evaluate the safety and effectiveness of the endometrial ablation device Librata in reducing menstrual blood loss at 12 months post-treatment when used in pre-menopausal women with menorrhagia…
- Trial name
- LEADER (NCT03725306)
- Testing
- Librata
- Volunteers
- 200 people
- Sponsor
- LiNA Medical
Recurrent Pregnancy Loss, Infertility, Female
Effects of PGS2.0 in Patients With Unexplained RPL
50%-60% of the known causes of recurrent pregnancy loss(RPL) are associated with embryonic aneuploidy, such that preimplantation genetic screening (PGS) on embryos acquired by assisted reproductive treatment should improve the…
- Trial name
- NCT03214185
- Testing
- IVF/ICSI, PGS 2.0, Conventional embryo morphology evaluation
- Where
- China
- Volunteers
- 710 people
- Sponsor
- ShangHai Ji Ai Genetics & IVF Institute
Vulvar Cancer, Vulvar Intraepithelial Neoplasia
The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence
In vulvar neoplasia, even minor surgical interventions cause multiple symptoms, symptom distress and complications, which have an impact on a woman's quality of life and contribute to high health care costs.
- Trial name
- WOMAN-PROII (NCT01986725)
- Testing
- standardized care (Intervention I), Standardized care + WOMAN-PRO II program (Intervention II)
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- St.Gallen University of Applied Sciences
Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN)
Epidemiological Factors and Optimization of Conservative Approaches to Precancerous Lesions of Female Reproductive Organs
The primary aim of this study is to develop a recommended clinical practice guideline for managing women with HPV HR (high-risk human papillomavirus) positivity and cervical lesions.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Risk Factors, Conservative Management
- Trial name
- NCT06967740
- Where
- Czechia
- Volunteers
- 200 people
- Sponsor
- Nikola Janovska
HIV Infections
Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women
The primary objective of the study was to evaluate the efficacy of nevirapine versus ZDV+3TC (Zidovudine + Lamivudine), when administered in labor and again at postdelivery, in reducing peripartum mother to child transmission of…
- Trial name
- NCT02181933
- Testing
- Nevirapine, Zidovudine (ZDV), Lamivudine (3TC)
- Volunteers
- 2,648 people
- Sponsor
- Boehringer Ingelheim
Epithelial Ovarian Cancer
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
Background: Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant.
- Trial name
- NCT05284552
- Testing
- Tinzaparin Injectable Solution
- Where
- 8 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- University Hospital, Linkoeping
Ovarian Neoplasms, Breast Neoplasms
Establishment of a Tumor Bank for Blood Samples
Establishment of a tumor bank, consisting of blood samples of tumor patients and healthy people as controls. The blood samples will be collected systematically together with the corresponding clinical data.
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Neoplasms of the Female Genitalia
- Trial name
- NCT01763125
- Testing
- Blood collection
- Where
- 6 sites in Austria, Belgium and 2 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with…
- Trial name
- NCT07198074
- Testing
- Bevacizumab, Biospecimen Collection, Carboplatin
- Where
- 304 sites in United States
- Volunteers
- 255 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Ovarian Cancer
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Background: Carboplatin is approved by the Food and Drug Administration to treat cancer. AZD2281 is an experimental drug in a class of agents called PARP inhibitors.
- Trial name
- NCT01445418
- Testing
- AZ2281 + Carboplatin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent or Metastatic Cervical Cancer
A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer
This is a study to evaluate the efficacy and safety of TQB2450 injection in the treatment of PD-L1 positive recurrent or metastatic cervical cancer.
- Trial name
- NCT04623333
- Testing
- TQB2450
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.